Dynavax Technologies Corporation logo
Dynavax Technologies Corporation DVAX

Quarterly report 2025-Q3
added 11-05-2025

report update icon

Dynavax Technologies Corporation Income Statement 2011-2026 | DVAX

Annual Income Statement Dynavax Technologies Corporation

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

1.73 B 1.61 B 1.36 B 1.51 B 636 M 359 M 687 M 863 M 148 M 792 M 450 M 345 M 515 M 443 M

Shares

130 M 129 M 126 M 116 M 101 M 72 M 62.4 M 52.6 M 38.5 M 32.9 M 26.3 M 19.6 M 17 M 12.5 M

Historical Prices

13.3 12.5 10.8 13 6.31 5.05 11 16.1 4.1 24.1 17.1 17.4 30.9 34.8

Net Income

27.3 M -6.39 M 293 M 76.7 M -75.2 M -153 M -159 M -95.2 M -112 M -107 M -90.7 M -66.7 M -69.9 M -48.6 M

Revenue

277 M 232 M 723 M 439 M 46.6 M 35.2 M 8.2 M 327 K 11 M 4.05 M 11 M 11.3 M 9.71 M 21.6 M

Cost of Revenue

49.4 M 50.2 M 262 M 174 M 11.4 M 10.2 M - - - - - - - -

Gross Profit

- - - - - 15.8 M -13.6 M - - 4.05 M 11 M 11.3 M 9.71 M 21.6 M

Operating Income

-4.12 M -37 M 284 M 134 M -68.4 M -135 M -153 M -96 M -111 M -105 M -91.3 M -66.5 M -67.6 M -47.6 M

Interest Expense

293 K -152 K 111 K 11.2 M 19.1 M 17 M 9.34 M -486 K -2.49 M 572 K 35 K -348 K 2.35 M 1.96 M

EBITDA

505 K -32.7 M 287 M 139 M -64.1 M -100 M -139 M -92 M -108 M -104 M -89.9 M -65.2 M -66.4 M -47.3 M

Operating Expenses

- - - - - 137 M 140 M 93.5 M 122 M 109 M 102 M 77.7 M 77.3 M 69.2 M

General and Administrative Expenses

170 M 153 M 131 M 100 M 79.3 M 75 M 64.8 M 27.4 M 37.3 M 22.2 M 17.8 M 26.9 M 28.2 M 17.6 M

All numbers in USD currency

Quarterly Income Statement Dynavax Technologies Corporation

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

117 M 119 M 125 M 125 M 131 M 131 M 130 M 130 M 129 M 129 M 128 M 128 M 127 M 126 M 125 M 123 M 117 M 115 M 112 M 110 M 110 M 97.3 M 85.5 M 83.9 M 75.1 M 65.1 M 63.8 M 62.7 M 62.6 M 62.3 M 61.7 M 61 M 57.6 M 49.7 M 41.8 M 38.5 M 38.5 M 38.5 M 38.5 M 38.4 M 36.5 M 29.3 M 27.1 M 26.3 M 26.3 M 26.3 M 26.3 M 23.6 M 183 M 183 M 183 M 181 M 178 M 168 M 155 M 142 M 124 M 118 M 116 M

Net Income

26.9 M 18.7 M -96.1 M - 17.6 M 11.4 M -8.72 M - 14.3 M 3.43 M -24.3 M - 63.8 M 129 M 32.9 M - -28.4 M 4.47 M 891 K - 4.4 M -51.6 M -12.6 M -36.8 M -33.5 M -42.7 M -39.7 M -40 M -40.5 M -39.4 M -39 M -27.4 M -22.1 M -20.3 M -25.3 M -21.7 M -34.7 M -29 M -27 M -26.9 M -30.1 M -23.6 M -26.2 M -22.3 M -29.8 M -24.8 M -13.8 M -13.1 M -15.7 M -17.2 M -20.8 M -20.5 M -17.8 M -15.1 M -16.5 M -4.27 M -15.2 M -10.6 M -18.5 M

Revenue

94.9 M 95.4 M 68.2 M - 80.6 M 73.8 M 50.8 M - 69.5 M 60.2 M 46.9 M - 168 M 256 M 114 M - 108 M 52.8 M 83.3 M - 13.4 M 2.67 M 10.9 M 10.6 M 10.6 M 8.3 M 5.77 M 5.32 M 1.46 M 1.25 M 165 K 21 K 53 K 105 K 148 K 7.29 M 162 K 2.65 M 942 K 685 K 1.19 M 1.55 M 627 K 2.28 M 2.21 M 3.05 M 3.5 M 2.85 M 2.93 M 3.39 M 2.08 M 1.81 M 2.87 M 2.68 M 2.35 M 11.4 M 1.17 M 7.27 M 1.74 M

Cost of Revenue

14.4 M 14 M 13.8 M - 13.1 M 12 M 11 M - 13.2 M 13.5 M 14.7 M - 61.3 M 83.4 M 40 M - 60.1 M - 24.6 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

21.3 M 14.4 M -23.6 M - 10.1 M 5.2 M -17.8 M - 5.12 M -3.4 M -30.2 M - 61.4 M 128 M 30.8 M - 16.1 M 9.17 M 28.5 M - -13.8 M -23.3 M -19.3 M - -30.6 M -39 M -37.9 M - -38.9 M -38.1 M -38.3 M - -22.4 M -20.3 M -25.5 M - -34.8 M -29.3 M -27.3 M - -28.4 M -23.2 M -26.5 M - -30.1 M -24.9 M -14 M - -15.6 M -17 M -20.9 M - -17.1 M -14.6 M -15.8 M - -14.8 M -10.1 M -17.9 M

Interest Expense

-27 K -596 K -423 K - -152 K 1.7 M 101 K - 266 K 1.69 M 1.69 M - 1.68 M 1.68 M 1.68 M - 1.68 M 3.11 M 4.71 M - 4.79 M 4.73 M 4.73 M - 4.78 M 4.6 M 2.73 M - 2.74 M 2.69 M 1.16 M - -166 K -232 K 20 K - -26 K 48 K 46 K - 62 K 263 K 247 K - 216 K 22 K 62 K - 24 K 27 K 32 K - 589 K 589 K 587 K - 485 K 487 K 490 K

EBITDA

- - -22.5 M - - - -16.6 M - - - -29.2 M - 64.4 M 128 M 31.7 M - 19.3 M 9.17 M 29.6 M - -10.7 M -21.3 M -18.3 M - -22.8 M -35.8 M -36.2 M - -36.4 M -36.5 M -37.5 M - -19.9 M -18.6 M -24.7 M - -33.3 M -28.3 M -26.9 M - -27.5 M -22.6 M -26.1 M - -29.1 M -24.2 M -13.6 M - -14.6 M -16.4 M -20.6 M - -16.2 M -14.1 M -15.6 M - -13.8 M -9.39 M -17.6 M

Operating Expenses

- - - - - - - - - - - - - - - - - - - - - - - - - 47.3 M 43.6 M - 40.4 M 39.4 M 38.5 M - 22.4 M 20.4 M 25.6 M - 35 M 31.9 M 28.2 M - 29.6 M 24.8 M 27.1 M - 32.3 M - - - - - - - - - - - - - -

General and Administrative Expenses

40.1 M 50.4 M 47.7 M - 43.1 M 41.7 M 44.1 M - 38.1 M 37.1 M 36.5 M - 32 M 36.2 M 32.2 M - 26.9 M 21.6 M 22.4 M - 21.5 M 19 M 20.9 M - 18.5 M 17.9 M 18.3 M - 15.8 M 15.7 M 16.9 M - 6.03 M 5.61 M 6.47 M - 11.8 M 9.15 M 8.17 M - 5.52 M 5.1 M 4.86 M - 4.08 M 4.08 M 4.16 M - 5.81 M 7.64 M 8.8 M - 7.12 M 5.96 M 5.79 M - 4.22 M 4.05 M 4.75 M

All numbers in USD currency

The income statement is one of the three key financial reports of a company Dynavax Technologies Corporation (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Benitec Biopharma Benitec Biopharma
BNTC
$ 10.98 -4.52 % $ 452 M usaUSA
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 221.88 -0.87 % $ 5 B danmarkDanmark
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Milestone Pharmaceuticals Milestone Pharmaceuticals
MIST
$ 1.36 -20.0 % $ 45.5 M canadaCanada
Pharming Group N.V. Pharming Group N.V.
PHAR
$ 15.36 -0.71 % $ 7.59 B niderlandNiderland
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Inventiva S.A. Inventiva S.A.
IVA
$ 5.78 -4.3 % $ 138 M franceFrance
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Tiziana Life Sciences PLC Tiziana Life Sciences PLC
TLSA
$ 1.21 -3.97 % $ 71.5 M britainBritain
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
PainReform Ltd. PainReform Ltd.
PRFX
$ 2.28 -0.44 % $ 1.03 M israelIsrael
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
- 10.36 % $ 9.8 M usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Assembly Biosciences Assembly Biosciences
ASMB
$ 28.46 3.45 % $ 319 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.37 -4.2 % $ 350 M britainBritain
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Axsome Therapeutics Axsome Therapeutics
AXSM
$ 156.92 -1.23 % $ 7.81 B usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
AbCellera Biologics AbCellera Biologics
ABCL
$ 3.4 -3.68 % $ 1.02 B canadaCanada
Atreca Atreca
BCEL
- -11.76 % $ 5.79 M usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
- -4.8 % $ 255 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
BioMarin Pharmaceutical BioMarin Pharmaceutical
BMRN
$ 54.13 -1.64 % $ 10.4 B usaUSA
Calithera Biosciences Calithera Biosciences
CALA
- -10.95 % $ 876 K usaUSA
Cara Therapeutics Cara Therapeutics
CARA
- -3.03 % $ 260 M usaUSA
ChemoCentryx ChemoCentryx
CCXI
- - $ 3.74 B usaUSA
Bellerophon Therapeutics Bellerophon Therapeutics
BLPH
- -74.18 % $ 955 K usaUSA
Compugen Ltd. Compugen Ltd.
CGEN
$ 2.09 -0.95 % $ 195 M israelIsrael
Coherus BioSciences Coherus BioSciences
CHRS
$ 1.52 -5.59 % $ 178 M usaUSA
Checkpoint Therapeutics Checkpoint Therapeutics
CKPT
- - $ 169 M usaUSA
Clovis Oncology Clovis Oncology
CLVS
- -7.23 % $ 13 M usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Burford Capital Limited Burford Capital Limited
BUR
$ 7.7 -5.87 % $ 1.29 B britainBritain
Corbus Pharmaceuticals Holdings Corbus Pharmaceuticals Holdings
CRBP
$ 8.6 -3.8 % $ 115 M usaUSA
Curis Curis
CRIS
$ 0.77 1.89 % $ 4.86 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA